Johnson & Johnson and Second Genome announced plans to collaborate on developing drugs that work on diseases such as ulcerative colitis by modifying intestinal bacteria. Second Genome, co-founded by former Pfizer innovation center president Corey Goodman, uses DNA sequencing to analyze organisms in a human stool sample, and then uses proprietary software to determine how drugs would affect the microbes.
J&J investment could be a tipping point for microbiome research
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|